Snapshot: July Highlights
Executive Summary
A selection of articles you may have missed from July 2023, including an interview with Abivax CEO Marc De Garidel, a roundup of biopharma dealmaking activity in the first half of 2023 and a look at Seres’ and Ferring’s launch strategies in recurrent C. diff market.
You may also be interested in...
Minute Insight: SpectralMD Signs Another Contract With BARDA, Worth $149m
The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.
Minute Insight: Vicarious’ Future Gets Precarious
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.
Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early
The UK-based company is hoping to quickly take market share with its blood-based diagnostic that uses epigenetic data to assist cancer diagnosis.